Clinical Trial Update: Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial update on ACH-126,443 (Beta-L-Fd4C) in treatment-naive adults with chronic hepatitis B exploring safety and antiviral activity; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ACH-126, 443 (Beta-L-Fd4C)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED